The rise and fall of intermittent interleukin-2 therapy in HIV infection.
In 1995, a breakthrough paper showed that intermittent cycles of interleukin-2 (IL-2), together with suboptimal ART, caused an unprecedented, stable increase in CD4+ T cell counts, without altering the steady state levels of viremia. At the time, this was somewhat obscured by the first successes of combination antiretroviral therapy (cART). However, since then, numerous studies have confirmed this basic finding, opening up a new perspective in the long-term management of chronic HIV infection. One of the benchmarks of this experimental treatment is the expansion of CD4+CD25+ T lymphocytes probably including T regulatory cells (Tregs). Based on these encouraging findings, two major phase III clinical trials, ESPRIT and SILCAAT, involving thousands of patients worldwide, were launched and continued over several years. Unfortunately, they both resulted in the highly unexpected, yet unequivocal, outcome of a lack of a protective effect of IL-2-expanded CD4+ T cells on HIV disease progression towards the acquired immunodeficiency syndrome (AIDS) or death. In addition, there was the suggestion of an increase in certain deleterious effects on treated patients in terms of cardiovascular and inflammatory events. While IL-2 therapy is unlikely to be studied any further in the context of HIV infection, other cytokines, such as IL-7, are still being tested in the hope of more promising results.
Della Chiara
Giulia
G
AIDS Immunopathogenesis Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy.
Fortis
Claudio
C
Tambussi
Giuseppe
G
Poli
Guido
G
D017326:Clinical Trials, Phase III as Topic; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007376:Interleukin-2 / Q000008:administration & dosage / Q000627:therapeutic use*
D007376:Interleukin-2